Overden salgılanan Hormonlar (Östrojen, Progesteron, Androjenler ve AMH)

Adashi EY, Rock JA. Reproductive Endocrinology, Surgery, and Teechnology,in Rosenwaks Z,editor. Lippncott-Raven, Philadelphia, 1996.

Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. Seventh edition. Baltimore, 2004; 45-97.

Şahmay, S:Temel Reprodüktif Endokrinoloji. Renk Matbaası, ISBN.978-975-01824-0-2, İstanbul. 2017.

Şahmay S. Foliküler matürasyon. Organon yayınları, Gestet Basım Tanıtım, İstanbul, 1996.

Holesh JE, Bass AN, Lord M Physiology, Ovulation. 2021; May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022

Howles CM, Ezcurra D, Homburg R. Ovarian stimulation protocols in assisted reproductive technology: an update. Expert Rev Endocrinol Metab. 2012; 7(3):319-330. doi: 10.1586/eem.12.18.

Şahmay S. Kadında reprodüktif aks ve folikülogenezis. Obstetrik ve Jinekoloji Sürekli Eğitim Dergisi, 1997; 1:207.

Atasü T, Şahmay S. Jinekoloji (Kadın Hastalıkları), yenilenmiş ve genişletilmiş 2. Baskı, Nobel Tıp Kitabevi, 2001.

Hekim N, Şahmay S. Hormon biyokimyasının prensipleri hormonlann yapısı, biyosentezi, etki mekanizması, endokrin, parakrin ve otokin kontrolü. In Atasü T, Şahmay S editors. Reproduktif Endokrinoloji, Nobel Tıp Kitabevi,1990; 51.

Coelingh Bennink HJT. Are all estrogens the same? Maturitas, 2004;47:269.

Yen SSC. Endocrine Physiology of Pregnancy, in Danforth DN, Scott JR,editors. Obstetrics and Gynecology, 10th edition, USA, JB Lippincott Co. Philadelphia, 2008; 340-65.

Frye CA. Steroids, reproductive endocrine function and affect. A review, Minerva Ginecol, 2009; 61(6):541-62.

Arunogiri S, Crossin R, Rizzo D, Walker L, Ridley K, Gurvich C. A systematic review of the effect of ovarian sex hormones on stimulant use in females. Addict Biol. 2021; 26(6):e13079. doi: 10.1111/adb.13079. Epub 2021

Weidlinger S, Schmutz C, Janka H, Gruetter C, Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review. Climacteric 2021; 24(6):551-559. doi: 10.1080/13697137.2021.1891218. Epub 2021 Mar 12.

Spark MJ, Willis J. Systematic review of progesterone use by midlife and menopausal women. Maturitas 2012; 72(3):192-202. doi: 10.1016/j.maturitas.2012.03.015.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012; 11;(7):CD004143. doi: 10.1002/14651858.CD004143.pub4.

Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013; 5;(6):CD009672. doi: 10.1002/14651858.CD009672.pub2.

Goldzieher JW. Pharmacodynamic effects of estrogens and progestogens. In Fraser IS, Jansen RPS, Lobo RA, Whitehead MI editors. Estrogens and Progestogens in Clinical Practice. Churchill Livingstone, London, 1998; 295.

Schneider HP. Androgens and antiandrogens. 2003; Ann N Y Acad Sci. 997:292.

Dutt M, Wehrle CJ, Jialal I. Physiology, Adrenal Gland. 2021 May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 30725945.

Şahmay S:Hiperandrojenism.ISBN.975-7970-01-8, Başkent ofset, İstanbul, 1997.

Fauser BCJM:Classification of chronic hyperandrogenic anovulation. In.Bennink HJTC, Vemer HM, vanKeep PA (eds), Chronic hyperandrogenic anovulation, The Parthenon Publishing Group, New Jersey, 13, 1991

Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(4):405-19. doi: 10.1093/humupd/dms013. Epub 2012 Apr 23.

Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2019;7(1):95-114. doi: 10.1016/j.sxmr.2018.06.002. Epub 2018 Aug 8.

Louise M. Bilezikjian, Wylie W. Vale. The Local Control of the Pituitary by Activin Signaling and Modulation. : Open Neuroendocrinol J. 2011; Jan 1; 4: 90–101. doi:10.2174/1876528901104010090

Bhide P, Pundir J, Homburg R, Acharya G. Biomarkers of ovarian reserve in childhood and adolescence: A systematic review. Acta Obstet Gynecol Scand. 2019; 98(5):563-572. doi: 10.1111/aogs.13574. Epub 2019 Mar 5.

Myers M, Pangas SA. Regulatory roles of transforming growth factor beta family members in folliculogenesis. Wiley Interdiscip Rev Syst Biol Med, 2010; 2(1):117-25.

Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011; 95(2):736 41.e13. doi:10.1016/j.fertnstert.2010.08.022. Epub 2010 Sep 24

Shankar KR, Dowlut-McElroy T, Dauber A, Gomez-Lobo V: J Clinical Utility of Anti-Mullerian Hormone in Pediatrics. Clin Endocrinol Metab. 2022;18;107(2):309-323. doi: 10.1210/clinem/dgab687

Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod. 2014;29(6):1117-21. doi: 10.1093/humrep/deu076. Epub 2014 Apr 25

La Marca A. et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 2010; Hum Reprod Update, 16:113.

Sahmay S, Guralp O, Senturk LM, Imamoglu M, Kucuk M, Irez T. Serum anti-müllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reprod Med Biol. 2011;10(2):113-120. doi: 10.1007/s12522-011-0078-5. eCollection 2011 Jun. PMID: 29699087

Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, Irez T. Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients. Reprod Med Biol. 2010;10(1):9-14. doi: 10.1007/s12522-010-0066-1. eCollection 2011 Mar. PMID: 29699077

Sahmay S, Aydogan Mathyk B, Sofiyeva N, Atakul N, Azemi A, Erel T. Serum AMH levels and insulin resistance in women with PCOS. Eur J Obstet Gynecol Reprod Biol. 2018;224:159-164. doi: 10.1016/j.ejogrb.2018.03.007. Epub 2018 Mar 22..

Sahmay S, Oncul M, Tuten A, Tok A, Acıkgoz AS, Cepni I. Anti-müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet . 2014;31(11):1469-74. doi: 10.1007/s10815-014-0324-y. Epub 2014 Sep 4.

Sahmay S, Tuten A, Gurleyen H, Oncul M, Benian A, Tamer Erel C. Diagnosis of late-onset congenital adrenal hyperplasia in clinical practice: current evaluation. Minerva Endocrinol. 2014;39(3):215-22.

Tuten A, Hatipoglu E, Oncul M, Imamoglu M, Acikgoz AS, Yilmaz N, Ozcil MD, Kaya B, Misirlioglu AM, Sahmay S. Evaluation of ovarian reserve in Hashimoto's thyroiditis. Gynecol Endocrinol. 2014;30(10):708-11. doi: 10.3109/09513590.2014.926324. Epub 2014 Jun 6.

Oncul M, Sahmay S, Tuten A, Acikgoz AS, Gurleyen HC. May AMH levels distinguish LOCAH from PCOS among hirsute women? Eur J Obstet Gynecol Reprod Biol . 2014;178:183-7. doi: 10.1016/j.ejogrb.2014.03.032. Epub 2014 Apr 12.

Tuten A, Sahmay S, Oncul M, Acikgoz AS, Imamoglu M, Gurleyen HC, Senturk ML. Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. Eur J Obstet Gynecol Reprod Biol. 2014;177:121-5. doi: 10.1016/j.ejogrb.2014.03.016. Epub 2014 Apr 2.

Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014;31(2):213-20. doi: 10.1007/s10815-013-0149-0. Epub 2013 Dec 18.

Sahmay S, Aydın Y, Atakul N, Aydogan B, Kaleli S. Relation of antimullerian hormone with the clinical signs of hyperandrogenism and polycystic ovary morphology Gynecol Endocrinol. 2014;30(2):130-4. doi: 10.3109/09513590.2013.867320. Epub 2013 Dec 16.

Sahmay S, Usta TA, Erel T, Atakul N, Aydogan B. Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric. 2014;17(2):197-203. doi: 10.3109/13697137.2013.870149. Epub 2014 Feb 4.

Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome Acta Obstet Gynecol Scand. 2013;92(12):1369-74. doi: 10.1111/aogs.12247. Epub 2013 Oct 15

Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol. 2013;170(1):157-61. doi: 10.1016/j.ejogrb.2013.05.019. Epub 2013 Jun 24.

Sahmay S, Guralp O, Aydogan B, Cepni I, Oral E, Irez T. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients, Gynecol Endocrinol. 2013;29(5):440-3. doi: 10.3109/09513590.2013.769519. Epub 2013 Mar 6

Sahmay S, Demirayak G, Guralp O, Ocal P, Senturk LM, Oral E, Irez T. Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. J Assist Reprod Genet. 2012;29(7):589-95. doi: 10.1007/s10815-012-9754-6. Epub 2012 Apr 11. PMID: 22492221

Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011;28(12):1197-203. doi: 10.1007/s10815-011-9627-4. Epub 2011 Sep 1. PMID: 21882017

Benian A, Guralp O, Uzun DD, Okyar A, Sahmay S. The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels Gynecol Endocrinol. 2013;29(3):226-9. doi: 10.3109/09513590.2012.738725.

Sahmay S, Usta T, Erel CT, Imamoğlu M, Küçük M, Atakul N, Seyisoğlu H. Is there any correlation between AMH and obesity in premenopausal women? Arch Gynecol Obstet. 2012;286(3):661-5. doi: 10.1007/s00404-012-2363-x. Epub 2012 May 4. PMID: 22552379

Depmann M, Eijkemans, S.L, Broer, GJ, Scheffer, van Rooij, IAJ, Laven,JSE, Broekmans, FJM; Does anti-Mullerian hormone predict menopause in the general population? Results of a prospective ongoing cohort Study Human Reprod. 2016; 31 (7):1579–87,

Moslehi N, Shab-Bidar S, Ramezani Tehrani F, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause. 2018;25(9):1046-1055. doi: 10.1097/GME.0000000000001116

Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis Hum Reprod Update. 2020;26(6):904-928. doi: 10.1093/humupd/dmaa013.

Muslim MZ, Jelani AM, Shafii N et al.:Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. L Ovarian Research, (2024) 17:106, doi.org/10.1186/s13048-024-01436

Mimouni NEH, Giacobini P.: Polycystic ovary syndrome (PCOS): progresstowards a better understanding and treatment of the syndrome. Comptes Rendus. Biologies2024, 347, 19-25, doi.org/10.5802/crbiol.147

Sardana K, Muddebihal A,Sehrawat M, et al.:An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists European Journal of Endocrinology, 2025, 192: 29–43 doi.org/10.1093/ejendo/lvaf062

Ham K, M.D.,Laven JSE, Tay CT, :Anti-m€ullerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis.Fertil Steril 2024;122:727–739

Piltonen, TT, Viita-aho J, Saarela U.:Utility of SerumAnti-Müllerian HormoneMeasurement as Part of Polycystic Ovary Syndrome Diagnosis. Semin Reprod Med 2024;42: 49–59

Adashi EY, Rock JA. Reproductive Endocrinology, Surgery, and Teechnology,in Rosenwaks Z,editor. Lippncott-Raven, Philadelphia, 1996.

Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. Seventh edition. Baltimore, 2004; 45-97.

Şahmay, S:Temel Reprodüktif Endokrinoloji. Renk Matbaası, ISBN.978-975-01824-0-2, İstanbul. 2017.

Şahmay S. Foliküler matürasyon. Organon yayınları, Gestet Basım Tanıtım, İstanbul, 1996.

Holesh JE, Bass AN, Lord M Physiology, Ovulation. 2021; May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022

Howles CM, Ezcurra D, Homburg R. Ovarian stimulation protocols in assisted reproductive technology: an update. Expert Rev Endocrinol Metab. 2012; 7(3):319-330. doi: 10.1586/eem.12.18.

Şahmay S. Kadında reprodüktif aks ve folikülogenezis. Obstetrik ve Jinekoloji Sürekli Eğitim Dergisi, 1997; 1:207.

Atasü T, Şahmay S. Jinekoloji (Kadın Hastalıkları), yenilenmiş ve genişletilmiş 2. Baskı, Nobel Tıp Kitabevi, 2001.

Hekim N, Şahmay S. Hormon biyokimyasının prensipleri hormonlann yapısı, biyosentezi, etki mekanizması, endokrin, parakrin ve otokin kontrolü. In Atasü T, Şahmay S editors. Reproduktif Endokrinoloji, Nobel Tıp Kitabevi,1990; 51.

Coelingh Bennink HJT. Are all estrogens the same? Maturitas, 2004;47:269.

Yen SSC. Endocrine Physiology of Pregnancy, in Danforth DN, Scott JR,editors. Obstetrics and Gynecology, 10th edition, USA, JB Lippincott Co. Philadelphia, 2008; 340-65.

Frye CA. Steroids, reproductive endocrine function and affect. A review, Minerva Ginecol, 2009; 61(6):541-62.

Arunogiri S, Crossin R, Rizzo D, Walker L, Ridley K, Gurvich C. A systematic review of the effect of ovarian sex hormones on stimulant use in females. Addict Biol. 2021; 26(6):e13079. doi: 10.1111/adb.13079. Epub 2021

Weidlinger S, Schmutz C, Janka H, Gruetter C, Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review. Climacteric 2021; 24(6):551-559. doi: 10.1080/13697137.2021.1891218. Epub 2021 Mar 12.

Spark MJ, Willis J. Systematic review of progesterone use by midlife and menopausal women. Maturitas 2012; 72(3):192-202. doi: 10.1016/j.maturitas.2012.03.015.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012; 11;(7):CD004143. doi: 10.1002/14651858.CD004143.pub4.

Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013; 5;(6):CD009672. doi: 10.1002/14651858.CD009672.pub2.

Goldzieher JW. Pharmacodynamic effects of estrogens and progestogens. In Fraser IS, Jansen RPS, Lobo RA, Whitehead MI editors. Estrogens and Progestogens in Clinical Practice. Churchill Livingstone, London, 1998; 295.

Schneider HP. Androgens and antiandrogens. 2003; Ann N Y Acad Sci. 997:292.

Dutt M, Wehrle CJ, Jialal I. Physiology, Adrenal Gland. 2021 May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 30725945.

Şahmay S:Hiperandrojenism.ISBN.975-7970-01-8, Başkent ofset, İstanbul, 1997.

Fauser BCJM:Classification of chronic hyperandrogenic anovulation. In.Bennink HJTC, Vemer HM, vanKeep PA (eds), Chronic hyperandrogenic anovulation, The Parthenon Publishing Group, New Jersey, 13, 1991

Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(4):405-19. doi: 10.1093/humupd/dms013. Epub 2012 Apr 23.

Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2019;7(1):95-114. doi: 10.1016/j.sxmr.2018.06.002. Epub 2018 Aug 8.

Louise M. Bilezikjian, Wylie W. Vale. The Local Control of the Pituitary by Activin Signaling and Modulation. : Open Neuroendocrinol J. 2011; Jan 1; 4: 90–101. doi:10.2174/1876528901104010090

Bhide P, Pundir J, Homburg R, Acharya G. Biomarkers of ovarian reserve in childhood and adolescence: A systematic review. Acta Obstet Gynecol Scand. 2019; 98(5):563-572. doi: 10.1111/aogs.13574. Epub 2019 Mar 5.

Myers M, Pangas SA. Regulatory roles of transforming growth factor beta family members in folliculogenesis. Wiley Interdiscip Rev Syst Biol Med, 2010; 2(1):117-25.

Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011; 95(2):736 41.e13. doi:10.1016/j.fertnstert.2010.08.022. Epub 2010 Sep 24

Shankar KR, Dowlut-McElroy T, Dauber A, Gomez-Lobo V: J Clinical Utility of Anti-Mullerian Hormone in Pediatrics. Clin Endocrinol Metab. 2022;18;107(2):309-323. doi: 10.1210/clinem/dgab687

Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod. 2014;29(6):1117-21. doi: 10.1093/humrep/deu076. Epub 2014 Apr 25

La Marca A. et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 2010; Hum Reprod Update, 16:113.

Sahmay S, Guralp O, Senturk LM, Imamoglu M, Kucuk M, Irez T. Serum anti-müllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reprod Med Biol. 2011;10(2):113-120. doi: 10.1007/s12522-011-0078-5. eCollection 2011 Jun. PMID: 29699087

Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, Irez T. Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients. Reprod Med Biol. 2010;10(1):9-14. doi: 10.1007/s12522-010-0066-1. eCollection 2011 Mar. PMID: 29699077

Sahmay S, Aydogan Mathyk B, Sofiyeva N, Atakul N, Azemi A, Erel T. Serum AMH levels and insulin resistance in women with PCOS. Eur J Obstet Gynecol Reprod Biol. 2018;224:159-164. doi: 10.1016/j.ejogrb.2018.03.007. Epub 2018 Mar 22..

Sahmay S, Oncul M, Tuten A, Tok A, Acıkgoz AS, Cepni I. Anti-müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet . 2014;31(11):1469-74. doi: 10.1007/s10815-014-0324-y. Epub 2014 Sep 4.

Sahmay S, Tuten A, Gurleyen H, Oncul M, Benian A, Tamer Erel C. Diagnosis of late-onset congenital adrenal hyperplasia in clinical practice: current evaluation. Minerva Endocrinol. 2014;39(3):215-22.

Tuten A, Hatipoglu E, Oncul M, Imamoglu M, Acikgoz AS, Yilmaz N, Ozcil MD, Kaya B, Misirlioglu AM, Sahmay S. Evaluation of ovarian reserve in Hashimoto's thyroiditis. Gynecol Endocrinol. 2014;30(10):708-11. doi: 10.3109/09513590.2014.926324. Epub 2014 Jun 6.

Oncul M, Sahmay S, Tuten A, Acikgoz AS, Gurleyen HC. May AMH levels distinguish LOCAH from PCOS among hirsute women? Eur J Obstet Gynecol Reprod Biol . 2014;178:183-7. doi: 10.1016/j.ejogrb.2014.03.032. Epub 2014 Apr 12.

Tuten A, Sahmay S, Oncul M, Acikgoz AS, Imamoglu M, Gurleyen HC, Senturk ML. Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. Eur J Obstet Gynecol Reprod Biol. 2014;177:121-5. doi: 10.1016/j.ejogrb.2014.03.016. Epub 2014 Apr 2.

Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014;31(2):213-20. doi: 10.1007/s10815-013-0149-0. Epub 2013 Dec 18.

Sahmay S, Aydın Y, Atakul N, Aydogan B, Kaleli S. Relation of antimullerian hormone with the clinical signs of hyperandrogenism and polycystic ovary morphology Gynecol Endocrinol. 2014;30(2):130-4. doi: 10.3109/09513590.2013.867320. Epub 2013 Dec 16.

Sahmay S, Usta TA, Erel T, Atakul N, Aydogan B. Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric. 2014;17(2):197-203. doi: 10.3109/13697137.2013.870149. Epub 2014 Feb 4.

Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome Acta Obstet Gynecol Scand. 2013;92(12):1369-74. doi: 10.1111/aogs.12247. Epub 2013 Oct 15

Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol. 2013;170(1):157-61. doi: 10.1016/j.ejogrb.2013.05.019. Epub 2013 Jun 24.

Sahmay S, Guralp O, Aydogan B, Cepni I, Oral E, Irez T. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients, Gynecol Endocrinol. 2013;29(5):440-3. doi: 10.3109/09513590.2013.769519. Epub 2013 Mar 6

Sahmay S, Demirayak G, Guralp O, Ocal P, Senturk LM, Oral E, Irez T. Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. J Assist Reprod Genet. 2012;29(7):589-95. doi: 10.1007/s10815-012-9754-6. Epub 2012 Apr 11. PMID: 22492221

Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011;28(12):1197-203. doi: 10.1007/s10815-011-9627-4. Epub 2011 Sep 1. PMID: 21882017

Benian A, Guralp O, Uzun DD, Okyar A, Sahmay S. The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels Gynecol Endocrinol. 2013;29(3):226-9. doi: 10.3109/09513590.2012.738725.

Sahmay S, Usta T, Erel CT, Imamoğlu M, Küçük M, Atakul N, Seyisoğlu H. Is there any correlation between AMH and obesity in premenopausal women? Arch Gynecol Obstet. 2012;286(3):661-5. doi: 10.1007/s00404-012-2363-x. Epub 2012 May 4. PMID: 22552379

Depmann M, Eijkemans, S.L, Broer, GJ, Scheffer, van Rooij, IAJ, Laven,JSE, Broekmans, FJM; Does anti-Mullerian hormone predict menopause in the general population? Results of a prospective ongoing cohort Study Human Reprod. 2016; 31 (7):1579–87,

Moslehi N, Shab-Bidar S, Ramezani Tehrani F, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause. 2018;25(9):1046-1055. doi: 10.1097/GME.0000000000001116

Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis Hum Reprod Update. 2020;26(6):904-928. doi: 10.1093/humupd/dmaa013.

Muslim MZ, Jelani AM, Shafii N et al.:Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. L Ovarian Research, (2024) 17:106, doi.org/10.1186/s13048-024-01436

Mimouni NEH, Giacobini P.: Polycystic ovary syndrome (PCOS): progresstowards a better understanding and treatment of the syndrome. Comptes Rendus. Biologies2024, 347, 19-25, doi.org/10.5802/crbiol.147

Sardana K, Muddebihal A,Sehrawat M, et al.:An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists European Journal of Endocrinology, 2025, 192: 29–43 doi.org/10.1093/ejendo/lvaf062

Ham K, M.D.,Laven JSE, Tay CT, :Anti-m€ullerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis.Fertil Steril 2024;122:727–739

Piltonen, TT, Viita-aho J, Saarela U.:Utility of SerumAnti-Müllerian HormoneMeasurement as Part of Polycystic Ovary Syndrome Diagnosis. Semin Reprod Med 2024;42: 49–59